Syn2bio (WAR:S2B) Accounts Payable: zł8.36 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
9 GF Score
Price zł64.00
! 1 Warning Sign
View Full Analysis

What is Syn2bio Accounts Payable?

Syn2bio WAR:S2B -0.44% 9 Accounts Payable is zł8.36 Mil as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

Syn2bio's Accounts Payable for the quarter that ended in Sep. 2025 was zł8.36 Mil.

Syn2bio's quarterly Accounts Payable declined from Sep. 2023 (zł1.45 Mil) to Sep. 2024 (zł0.32 Mil) but then increased from Sep. 2024 (zł0.32 Mil) to Sep. 2025 (zł8.36 Mil).

Syn2bio's annual Accounts Payable declined from Sep. 2023 (zł1.45 Mil) to Sep. 2024 (zł0.32 Mil) but then increased from Sep. 2024 (zł0.32 Mil) to Sep. 2025 (zł8.36 Mil).

Syn2bio Accounts Payable Historical Data

* Premium members only.

The historical data trend for Syn2bio's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio Accounts Payable Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
Accounts Payable
1.45 0.32 8.36

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
Accounts Payable 1.45 0.32 8.36
WAR:S2B
9GF Score
Syn2bio SA WAR:S2B
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of zł8.36 Mil mean?
Syn2bio (WAR:S2B) has a Accounts Payable of zł8.36 Mil as of Sep. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Syn2bio and its competitors.
Is Syn2bio's Accounts Payable too high?
Syn2bio's current Accounts Payable is zł8.36 Mil. Overall, Syn2bio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's Accounts Payable compare to VRTX and REGN?
Syn2bio's Accounts Payable of zł8.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Syn2bio and its competitors. Syn2bio's current Accounts Payable is zł8.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current Accounts Payable of zł8.36 Mil. The current Accounts Payable is zł8.36 Mil. Syn2bio's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current Accounts Payable is zł8.36 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
9GF Score

Get the complete analysis for WAR:S2B

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł64.00
Price